Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vonoprazan-based versus esomeprazole-based triple therapy for Helicobacter pylori eradication
IRCT20250919067288N1Phase 2Completed
- Sponsor
- Ahvaz Jundishapur University of Medical Sciences
- Start
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of vonoprazan, esomeprazole, amoxicillin and clarithromycin in Helicobacter pylori infection (2 arms), sponsored by Ahvaz Jundishapur University of Medical Sciences. Primary endpoints: Helicobacter pylori eradication rate and Safety and adverse effects of treatment. Started Oct 2025; status: completed.
02
Drugs
vonoprazanesomeprazoleamoxicillinclarithromycin
03
Conditions
Helicobacter pylori infection
Beyond the preview
Go deeper on IRCT20250919067288N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20250919067288N1.